The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
10 2021
Historique:
revised: 19 04 2021
received: 13 02 2021
accepted: 03 05 2021
pubmed: 11 6 2021
medline: 3 11 2021
entrez: 10 6 2021
Statut: ppublish

Résumé

The 10-item Alcohol Use Disorders Identification Test (AUDIT-10) and its shorter form, AUDIT-Consumption (AUDIT-C), are questionnaires used to characterize severity of drinking. We hypothesized that liver injury and short-term outcomes of alcohol-associated hepatitis (AH) would correlate with a patient's recent alcohol consumption as determined by AUDIT-10 and AUDIT-C. We analyzed a prospective international database of patients with AH diagnosed based on the National Institute on Alcohol Abuse and Alcoholism (NIAAA) standard definitions. All patients were interviewed using AUDIT-10. Primary outcomes included the discriminatory ability of the AUDIT-10 and AUDIT-C scores for predicting survival status at 28 and 90 days and severity of liver injury, as measured by Model for End-Stage Liver Disease-sodium (MELD-Na). The relationship between AUDIT scores and survival status was quantified by calculating the area under the curve of the receiver operating characteristic analysis. The relationship between AUDIT scores and MELD-Na was examined using correlation coefficients. In 245 patients (age range 25-75 years; 35% female), we found no correlation between AUDIT-10 or AUDIT-C scores and either 28- or 90-day mortality. Similarly, there was no correlation between AUDIT-10 and AUDIT-C and MELD-Na scores. There was a strong positive correlation between MELD-Na and 28- and 90-day mortality. Additional measures of severity of alcohol use (average grams of alcohol consumed per day, years of drinking, convictions for driving under the influence, and rehabilitation attempts) and psychosocial factors (marriage, paid employment, and level of social support) had no influence on MELD-Na. In patients presenting with AH, AUDIT-10 and AUDIT-C were predictors of neither clinical severity of liver disease nor short-term mortality, suggesting that level of alcohol consumption in the prior year is not key to the presenting features or outcome of AH.

Identifiants

pubmed: 34109723
doi: 10.1002/lt.26203
pii: 01445473-202110000-00008
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1382-1391

Subventions

Organisme : NIAAA NIH HHS
ID : U01 AA026939
Pays : United States

Informations de copyright

Copyright © 2021 by the American Association for the Study of Liver Diseases.

Références

Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12‐month alcohol use, high‐risk drinking, and DSM‐IV alcohol use disorder in the United States, 2001‐2002 to 2012‐2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017;74:911–923.
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758–2769.
Louvet A, Naveau S, Abdelnour M, Ramond M‐J, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348–1354.
Conigrave KM, Saunders JB, Reznik RB. Predictive capacity of the AUDIT questionnaire for alcohol‐related harm. Addiction 1995;90:1479–1485.
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol‐associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020;71:306–333.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 2016;150:785–790.
Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897–903.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993;88:791–804.
Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987–990.
Altamirano J, Higuera‐de laTijera F, Duarte‐Rojo A, Martínez‐Vázquez MA, Abraldes JG, Herrera‐Jiménez LE, et al. The amount of alcohol consumption negatively impacts short‐term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol 2011;106:1472–1480.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–1465.
Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21–23.
Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology 2017;66:1464–1473.
Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long‐term prognosis. Am J Gastroenterol 1971;56:515–525.
Altamirano J, López‐Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long‐term survival. Hepatology 2017;66:1842–1853.
Thursz M, Kamath PS, Mathurin P, Szabo G, Shah VH. Alcohol‐related liver disease: areas of consensus, unmet needs and opportunities for further study. J Hepatol 2019;70:521–530.
Liangpunsakul S, Puri P, Shah VH, Kamath P, Sanyal A, Urban T, et al. Effects of age, sex, body weight, and quantity of alcohol consumption on occurrence and severity of alcoholic hepatitis. Clin Gastroenterol Hepatol 2016;14:1831–1838.e1833.
Weinrieb RM, Van Horn DH, McLellan AT, Lucey MR. Interpreting the significance of drinking by alcohol‐dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl 2000;6:769–776.
Orrego H, Blake JE, Blendis LM, Kapur BM, Israel Y. Reliability of assessment of alcohol intake based on personal interviews in a liver clinic. Lancet 1979;2:1354–1356.
Lourens S, Sunjaya DB, Singal A, Liangpunsakul S, Puri P, Sanyal A, et al. Acute alcoholic hepatitis: natural history and predictors of mortality using a multicenter prospective study. Mayo Clin Proc Innov Qual Outcomes 2017;1:37–48.
Peeraphatdit TB, Kamath PS, Karpyak VM, Davis B, Desai V, Liangpunsakul S, et al. Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2020;18:477–485.e475.
Daniel KE, Lucey MR. Editorial: moderate alcoholic hepatitis‐hiding in plain sight. Aliment Pharmacol Ther 2019;50:608–609.

Auteurs

Jessica A Musto (JA)

Division of Gastroenterology and Hepatology University of Wisconsin School of Medicine and Public Health Madison WI University of Pittsburgh Medical Center Pittsburgh PA Liver Unit Hospital Universitari Vall d'HebronUniversitat Autònoma de Barcelona Barcelona Spain Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) Barcelona Spain Division of Gastroenterology, Liver Unit University of Alberta Edmonton AB Canada Hospital Universitario, Departamento de Gastroenterología Universidad Autonoma de Nuevo Leon Monterrey Mexico Division of Digestive and Liver DiseasesDepartment of Medicine Columbia College of Physicians and SurgeonsColumbia University Medical Center New York NY Division of Gastroenterology and Hepatology Weill Cornell Medical College New York NY Liver Unit, Hospital Clinic Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Barcelona Spain Institute of Liver Studies King's College London School of Medicine at King's College HospitalKing's College Hospital London United Kingdom Service des Maladies de L'appareil Digestif et Unité INSERM Hôpital Huriez Lille France Section of Digestive Diseases Yale University School of Medicine New Haven CT Section of Digestive Diseases VA-CT Healthcare System West Haven CT UC San Diego San Diego CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH